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Folic acid enhances endothelial function and improves outcome in primary prevention of cardiovascular
disease. The exact intracellular signalling mechanisms involved remain elusive and were therefore the
subject of this study. Particular focus was placed on folic acid-induced changes in posttranslational
modiﬁcations of endothelial nitric oxide synthase (eNOS). Cultured endothelial cells were exposed
to folic acid in the absence or presence of phosphatidylinositol-3' kinase/Akt (PI3K/Akt) inhibitors.
The phosphorylation status of eNOS was determined via western blotting. The activities of eNOS and
PI3K/Akt were evaluated. The interaction of eNOS with caveolin-1, Heat-Shock Protein 90 and calmodulin
was studied using co-immunoprecipitation. Intracellular localisation of eNOS was investigated using
sucrose gradient centrifugation and confocal microscopy. Folic acid promoted eNOS dephosphorylation
at negative regulatory sites, and increased phosphorylation at positive regulatory sites. Modulation of
phosphorylation status was concomitant with increased cGMP concentrations, and PI3K/Akt activity.
Inhibition of PI3K/Akt revealed speciﬁc roles for this kinase pathway in folic acid-mediated eNOS
phosphorylation. Regulatory protein and eNOS protein associations were altered in favour of a positive
regulatory effect in the absence of bulk changes in intracellular eNOS localisation. Folic acid-mediated
eNOS activation involves the modulation of eNOS phosphorylation status at multiple residues and
positive changes in important protein–protein interactions. Such intracellular mechanisms may in part
explain improvements in clinical vascular outcome following folic acid treatment.
& 2013 The Authers. Published by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Controversy exists as to the role of folic acid in the prevention/
treatment of cardiovascular disease. However, our own studies
have shown six weeks of daily folic acid (5 mg) supplementation
in patients with coronary artery disease to improve endothelial
function, independently of homocysteine lowering (Doshi et al.,
2001, 2002; Moat et al., 2006b). Further in vitro investigations
demonstrate that the folic acid-mediated improvement in endo-
thelial function involves increased endothelial nitric oxide (NO)
synthase (eNOS) dimerisation (Moat et al., 2006b), independently
of tetrahydrobiopterin levels or an antioxidant effect (Moat et al.,
2006a).B.V.
e, School of Medicine, Cardiff
, UK. Tel.: +44 2920742058;
Open access under CC BY-NC-ND licenNumerous other studies have shown folic acid to produce
signiﬁcant improvements in endothelial function (Bellamy et al.,
1999; Chambers et al., 2000; Shirodaria et al., 2007), however,
secondary prevention studies have found no beneﬁcial effect
of folic acid on clinical outcomes in patients with established
cardiovascular disease (Albert et al., 2008; Bonaa et al., 2006;
Ebbing et al., 2008; Hankey et al., 2010; Lonn et al., 2006; Toole
et al., 2004). This suggests that the endothelium is perhaps
“beyond repair” in the latter populations while optimised endo-
thelial function is crucial in preventing a ﬁrst ever vascular event.
An understanding of the mechanism(s) by which folic acid
improves endothelial function is therefore essential.
A major contributor to cardiovascular health is the bioavail-
ability of eNOS-derived NO. A complex series of post-translational
events tightly regulates eNOS function (Raﬁkov et al., 2011), in
particular, changes in phosphorylation at multiple serine (Ser) and
threonine (Thr) residues (Mount et al., 2007). Negative regulation
occurs through increased eNOS phosphorylation at Ser114/6
(Li et al., 2007) and Thr495/7 (Fleming et al., 2001), while positive
regulation occurs through increased phosphorylation at Ser633/5
and Ser1177/9 (Boo et al., 2003; Dimmeler et al., 1999; Fulton et al.,
1999; McCabe et al., 2000). Such changes are thought to be
mediated via the actions of several serine/threonine kinases, inse.
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et al., 2007).
Further control is provided by interactions of eNOS with other
proteins (Fulton et al., 2001; Kone et al., 2003) such as that with
caveolin-1 within plasmalemmal caveolae (Feron et al., 1996;
Shaul et al., 1996). In this location caveolin-1 acts as an eNOS
inhibitor, preventing inappropriate release of NO under “resting”
conditions (Ju et al., 1997). Upon endothelial cell activation eNOS
interacts with the calcium/calmodulin (Ca2+/calmodulin) complex
and dissociates from caveolin-1 (Michel et al., 1997a). A subse-
quent interaction between eNOS and Heat-Shock Protein 90
(HSP90) is thought to further increase eNOS activity by facilitating
Ca2+/calmodulin-associated dissociation from caveolin-1 (Gratton
et al., 2000). Given the above, it would seem that the precise
intracellular location of eNOS is also imperative with regard to
achieving optimal enzyme activity. Indeed, that targeting eNOS to
intracellular membrane domains is necessary for stimulated NO
release (Sakoda et al., 1995; Sessa et al., 1995; Sullivan and Pollock,
2003), and Ser1179-phosphorylated eNOS becomes speciﬁcally
localised to Golgi and plasma membrane pools of active enzyme
(Fulton et al., 2002) supports this notion.
As such, determining the effects of folic acid on eNOS
phosphorylation, protein–protein interactions and intracellular
location/distribution is vital in understanding the mechanisms
by which folate-mediated cardioprotection may arise.2. Materials and methods
2.1. Cell culture
Porcine aortic endothelial cells were isolated as previously
described (Moat et al., 2006b). Cells were grown to 80% conﬂuence
in Medium 199 (Life Technologies, Paisley, UK) containing 10%
(v/v) foetal calf serum and 1% (w/v) penicillin/streptomycin in
Primaria-coated ﬂasks (Promega, Southampton, UK) before sub-
culture at a ratio of 1:4. Conﬂuent cells were serum starved
overnight and before exposure to appropriate agents. All experi-
ments were performed in serum-free medium.
2.2. Cell incubations
To investigate the time-dependent effects of folic acid on eNOS
phosphorylation porcine aortic endothelial cells were incubated
with either vehicle (serum-free medium, Control) or 5 μM folic
acid (concentration based on a previous study, Moat et al., 2006b)
for 1, 2, 4, 8, 16 or 24 h. The concentration-dependent effects of
folic acid on eNOS phosphorylation were subsequently investi-
gated by incubation of cells with either vehicle (Control) or 0.5,
5 or 50 mM folic acid (concentration range based on a previous
study, Moat et al., 2006b) for 24 h.
In other experiments, and 30min before addition of either vehicle
or folic acid (5 mM, 24 h), some cultures received cell permeable
PI3K/Akt inhibitors: wortmannin (100 nM) or LY294002 (10 mm).
Following each experiment cells were washed twice in ice-cold
sterile 0.9% (w/v) saline then scraped into the appropriate lysis
buffer.
2.3. Western blotting
Porcine aortic endothelial cells were lysed on ice for 30 min in
modiﬁed radioimmunoprecipitation assay buffer (150 mM sodium
chloride, 1% v/v Triton-X 100, 0.5% w/v deoxycholic acid, 0.1% w/v
SDS, 50 mM Tris, pH 8.0) containing Complete Protease Inhibitor
Cocktail (Roche, Welwyn Garden City, UK) and Halt™ Phosphatase
Inhibitor Cocktail (Fisher Scientiﬁc Ltd, Loughborough, UK).Following centrifugation (16,000 g at 4 1C for 15 min) supernatant
total protein content was determined by Coomassie protein assay.
Reducing sodium dodecyl sulphate polyacrylamide gel electro-
phoresis was used to separate 20 mg of protein per well into a 7.5%
gel, followed by transfer onto Hybond P membrane (GE Healthcare
Life Sciences, Buckinghamshire, UK) using methanol-based wet
transfer at 4 1C for 2 h. Subsequently membranes were blocked
overnight in 1% (w/v) non-fat milk/Tris-buffered saline Tween
for eNOS or phospho-eNOS detection. For β-actin, caveolin-1 and
calmodulin 5% (w/v) non-fat milk/Tris-buffered saline Tween was
used. For HSP90 detection blocking was not applied. Phosphory-
lated proteins were ﬁrst detected in membranes using rabbit anti-
human phospho-eNOS Ser114/6, rabbit anti-bovine phospho-eNOS
Ser633/5, rabbit anti-human phospho-eNOS Thr495/7 (all Milli-
pore Ltd, Oxfordshire, UK), mouse anti-human phospho-eNOS
Ser1177/9 (BD, Oxford, UK) and rabbit anti-human phospho-Akt
Ser473 (Abcam, Cambridge, UK) primary antibodies. As appropri-
ate membranes were then stripped and reprobed for total eNOS
or Akt followed by detection of β-actin (using mouse anti-human
eNOS (BD, Oxford, UK), rabbit anti-mouse Akt (New England
Biolabs, Hitchin, UK) and goat anti-human β-actin (Santa Cruz
Biotechnology, Heidelberg, Germany) primary antibodies). Alter-
natively the total protein levels of soluble guanylate cyclase, PI3K,
caveolin-1, HSP90 or calmodulin were determined using rabbit
anti-human soluble guanylate cyclase (Abcam, Cambridge, UK),
PI3K, caveolin-1 (both Santa Cruz Biotechnology, Heidelberg,
Germany), HSP90 and calmodulin (both Abcam, Cambridge, UK),
and then membranes stripped and reprobed for β-actin (as above).
Secondary HRP-conjugated antibody and enhanced chemilumi-
nescence (Santa Cruz Biotechnology, Heidelberg, Germany) were
used to visualise immunoreactive protein bands on photographic
ﬁlm (GE Healthcare Life Sciences, Buckinghamshire, UK).
Photographic ﬁlms were scanned using a GS700 Densitometer
and quantiﬁcation achieved using Quantity One software (both
Biorad, Hemel Hempstead, UK). Total eNOS, Akt, soluble guanylate
cyclase, PI3K, caveolin-1, HSP90 and calmodulin were normalised
to β-actin and then as a ratio to control in the absence of folic acid
as appropriate. Phosphorylation of eNOS or Akt was expressed as
the ratio of phosphorylated/total protein optical density (ODu) and
then as a ratio to control in the absence of folic acid as appropriate.
2.4. Activity of eNOS
Porcine aortic endothelial cell cGMP content was measured as
an index of eNOS activity. Following appropriate incubations in
a concentration range of folic acid with some being performed
in the presence of the eNOS inhibitor NG-nitro-L-arginine-methyl
ester (L-NAME, 100 mM) cells were stimulated with calcium iono-
phore A23187 (10 mM) for 30 min. In additional experiments cells
were incubated with the PI3K and PKA inhibitors in the absence
and presence of 5 μM folic acid as described above.
At appropriate end points cells were scraped into 0.1 M hydro-
chloric acid and cGMP concentration determined by commercial
immuno-based assay (Abcam, Cambridge, UK) according to man-
ufacturer instructions. Total lysate protein concentrations were
measured by Coomassie protein assay, and cGMP concentration
normalised.
2.5. Co-immunoprecipitation
Porcine aortic endothelial cells were treated as described
previously before scraping into immunoprecipitation lysis buffer
provided in the Classic IP kit (Thermo Fisher Scientiﬁc, Rockford,
IL, USA). Co-immunoprecipitation was performed as per kit instruc-
tions using rabbit anti-human eNOS primary antibody to couple eNOS
in lysates to protein A/G agarose beads.
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To investigate the cellular location of eNOS following folic acid
stimulation conﬂuent, serum starved and appropriately treated
porcine aortic endothelial cells (T75 ﬂask) were scraped into
0.5 ml 500 mM sodium carbonate, pH 11. Lysates were Dounce
homogenised and sonicated (320 s bursts at 30% maximum
power). For a ﬁnal sample volume of 2 ml, lysates from 4T75
ﬂasks were pooled. To adjust the lysate sucrose concentration
to 42.5% (w/v) sucrose, 2 ml 85% (w/v) sucrose prepared in
2-(N-morpholino)ethanesulfonic acid (MES)-buffered saline
(25 mM MES, pH 6.5, 0.15 M sodium chloride) was added to the
lysate in an ultracentrifuge tube. As previously described (Fulton
et al., 2002), a discontinuous sucrose gradient (5–30% w/v) was
then formed above the lysate by adding 5 ml 30% (w/v) sucrose
then 6 ml 5% (w/v) sucrose in MES-buffered saline containing
250 mM sodium carbonate followed by centrifugation at 125,755 g
for 24 h using an SW32 Ti rotor (Beckman Coulter (UK) Ltd, High
Wycombe). Following this procedure, the 5–30% sucrose interface
is characterised by the presence of cholesterol-rich microdomains
(lipid rafts and caveolae), larger soluble proteins and heavy
membranes remain at the bottom of the gradient. Gradient
fractions were collected from the top of the gradient (1 ml
per fraction) and the presence of eNOS, eNOS Ser1179p and
caveolin-1 (antibodies as above) analysed using western blotting
as described above.
2.7. Confocal microscopy
Porcine aortic endothelial cells were isolated and cultured as
previously described and plated onto sterile coverslips. Cells were
then treated with either vehicle or folic acid (5 μM) as appropriate
for 24 h before being ﬁxed with para-formaldehyde (2% w/v in
0.1 M Tris-buffered saline, pH 7.4 for 15 min). Subsequently cells
were washed (35 min in phosphate-buffered saline) before
exposure to blocking solution (phosphate-buffered saline contain-
ing 5% v/v donkey serum, 1% w/v bovine serum albumin and 0.1%
v/v triton X-100) for 1 h. Primary antibody (or blocking solution
alone for negative controls) was then added as appropriate and the
ﬁxed endothelial cells left to react overnight at 4 1C. Following
removal of excess antibody by 315 min washes in phosphate-
buffered saline, ﬁxed endothelial cells were then incubated with
an appropriate ﬂuorescence-conjugated secondary antibody for
2 h. After further phosphate-buffered saline washes (315 min)
coverslips were mounted on slides and kept in the dark. Fluor-
escent labelling was visualised using a Leica SP2 confocal micro-
scope and images captured using Leica software.
2.8. Statistical analysis
Experimental data is representative of n≥3 independent experi-
ments expressed as mean7standard error of the mean. Analysis
of variance was used for multiple comparisons, followed
by appropriate post-hoc analysis. Differences were considered
signiﬁcant at nPo0.05, nnPo0.01, and nnnPo0.001.3. Results
3.1. Folic acid and changes in total protein
Total protein levels of eNOS (Fig. 1A and E) and β-actin and
(Fig. 1B and E) were unaffected by exposure to 5 μM folic acid from
1 to 24 h or by exposure to a concentration range of folic acid
(0.5–50 μM) for 24 h. Total soluble guanylate cyclase (Fig. 2B), PI3K
(Fig. 3B) and Akt (Fig. 3B) protein levels were similarly unalteredfollowing exposure to a concentration range of folic acid
(0.5–50 μM) for 24 h. Exposure to PI3K/Akt inhibitors wortmannin
and LY294002 in the absence and presence of 5 μM folic acid over
24 h did not result in changes in total β-actin or eNOS (Fig. 3A).
Before co-immunoprecipitation with eNOS protein, and after
exposure to a concentration range of folic acid (0.5–50 μM) for
24 h, total cellular levels of β-actin, eNOS, and the eNOS regulatory
proteins HSP90, caveolin-1 and calmodulin were not altered
(Fig. 4A). This indicates that incubations did not alter the tran-
scription/translation of these proteins per se.
3.2. Folic acid and modulation of eNOS phosphorylation
Phosphorylation of eNOS at the positive regulatory residue
Ser1179 was increased after exposure to 5 μM folic acid for 24 h
(Fig. 1C). No change in phosphorylation was observed at the 1, 2, 4,
8 or 16 h time points (Fig. 1C). Similarly decreased phosphoryla-
tion at the negative regulatory site Thr497 was also observed post-
5 μM folic acid treatment (Fig. 1D). Interestingly this site would
seem to be more sensitive to the effects of folic acid, the change
being signiﬁcant at both the 16 and 24 h time points. The 24 h
time point was subsequently used for experiments investi-
gating the effects of a concentration range of folic acid on eNOS
phosphorylation.
Following 24 h exposure of porcine aortic endothelial cells to
increasing concentrations of folic acid, phosphorylation of eNOS at
the positive regulatory sites Ser635 and Ser1179 was augmented
compared to controls (Fig. 1E). Sensitivity was greatest at Ser1179,
with signiﬁcant effects ﬁrst observed at 0.5 mM (Fig. 1E) compared to
5 mM for Ser635 (Fig. 1E). The biggest changes in phosphorylation at
these sites were also strikingly different as evidenced by a 300–400%
increase at Ser1179 compared with only 100–150% at Ser635.
In the same experiments decreased phosphorylation of eNOS at
the negative regulatory sites Ser116 and Thr497 was also observed
(Fig. 1E). As in the temporal experiment, sensitivity was greatest at
Thr497, with signiﬁcant effects ﬁrst observed at 0.5 mM folic acid
compared to 5 mM for Ser116 (Fig. 1E). The maximum decreases in
phosphorylation were similar at both sites.
3.3. Folic acid and eNOS activity: effects of protein kinase inhibition
Exposure of untreated porcine aortic endothelial cells to calcium
ionophore A23187 produced an approximate 10-fold increase in
cGMP (an index of eNOS activation) above baseline values (Fig. 2A).
In the presence of folic acid signiﬁcant concentration-dependent
increases in both basal and A23187-stimulated endothelial cells
cGMP levels were observed (Fig. 2A). That eNOS-derived NO
mediates the elevation in cGMP is conﬁrmed by the inhibitory action
of L-NAME on these responses (Fig. 2A).
The presence of PI3K/Akt inhibition prevented A23187-
stimulated increases in cGMP in both control (0.3070.17 and
0.2170.06 fmol/mg protein respectively for wortmannin and
LY294002 cf 1140.417174.49 fmol/mg protein in their absence)
and folic acid-treated cells (0.3070.17 and 0.2170.06 fmol/mg
protein respectively for wortmannin and LY294002 cf 4624.107
417.01 fmol/mg protein in their absence).
3.4. Folic acid and eNOS phosphorylation: effects of PI3K/Akt
inhibition
The PI3K/Akt inhibitors wortmannin and LY294002 mediated
a signiﬁcant increase in phosphorylation at Ser116 (Fig. 3A) and
signiﬁcant decreases at Thr497, Ser635 and Ser1179 (Fig. 3A). In
the presence of such inhibition folic acid was unable to promote
the changes in phosphorylation at Ser116, Thr497, Ser635 and
Ser1179 described above.
Fig. 1. Folic acid modulates eNOS phosphorylation status. Western blotting and densitometric analysis of porcine aortic endothelial cell lysates was used to assess the effects
of folic acid (FA, 5 μM) incubation over 1–24 h (A–D), and a concentration range of folic acid (0–50 μM) for 24 h (E) on total eNOS, β-actin and eNOS Ser116p, Thr497p,
Ser635p and Ser1179p (eNOS was normalised to β-actin levels and Ser116p, Thr497p, Ser635p and Ser1179p normalised to total eNOS). Appropriate representative blots are
shown. Molecular weight of proteins given in kDa. nPo0.05, nnPo0.01, nnnPo0.001 cf the appropriate “Control”.
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Exposure of porcine aortic endothelial cells to increasing
concentrations of folic acid (0.5–50 μM) for 24 h had no effect
on total levels of PI3K and Akt (Fig. 3B). A signiﬁcant increase in
Ser473-phosphorylated Akt (pAkt, an indicator of PI3K/Akt activ-
ity) was evident in the presence of the highest concentration of
folic acid (Fig. 3B).
3.6. Regulatory protein association with eNOS
Folic acid treatment did not alter total eNOS, caveolin-1, HSP90 or
calmodulin protein levels (Fig. 4A). However, co-immunoprecipitation
revealed a concentration-dependent decrease in the interaction ofeNOS with caveolin-1 (Fig. 4B) and an increase in that of eNOS with
HSP90 (Fig. 4B). Folic acid had no effect on the interaction of eNOS and
calmodulin (Fig. 4B).
3.7. Cellular localisation
Following discontinuous sucrose gradient ultracentrifugation,
western blotting was used to identify proteins in the various
cell fractions. Conﬁrmation of adequate cellular separation was
provided by the presence of the cytoskeletal protein β-actin in
fractions 12–14 (soluble proteins and heavy membranes) (Fig. 5B)
and the plasma membrane caveolae protein caveolin-1 in fractions
6–9 (buoyant cholesterol-rich light membranes) (Fig. 5D). Western
blotting for both total eNOS and eNOS Ser1179p revealed that
Fig. 2. Folic acid modulates eNOS phosphorylation activity. Activity of eNOS post
folic acid incubation (0–50 mM, 24 h) was assessed indirectly via cGMP assay in
unstimulated (Basal) porcine aortic endothelial cells (PAEC) and following calcium
ionophore A23187 (Ionophore) stimulation in the absence or presence of L-NAME
(A). Western blotting and densitometric analysis of PAEC lysates was used to assess
the effect of folic acid (FA, 0–50 μM, 24 h) incubation on total soluble guanylate
cyclase protein (sGC) (B). Appropriate representative blots are shown. Molecular
weight of proteins given in kDa. #Po0.01 cf basal; nPo0.05, nnPo0.01,
nnnPo0.001 cf Ionophore in the absence of folic acid (C).
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sponding to both light membrane and heavy membrane fractions
(Fig. 5A and C respectively). No obvious change in the distribution
of total eNOS protein or eNOS Ser1179p was found following
stimulation with 5 mM folic acid (Fig. 5A and C respectively).
Confocal microscopy was used to conﬁrm the subcellular
location of porcine aortic endothelial cell eNOS in the absence
and presence of folic acid (0.5, 5 or 50 mM for 24 h). Interestingly
eNOS protein was found localised to both the perinuclear region in
a “punctate vesicular pattern” (similar to that previously described
(Fulton et al., 2002) and most likely representing a Golgi localised
enzyme pool (Sowa et al., 1999)) and the periphery (most likely to
representing a caveolae-localised enzyme pool) (Fig. 5E). Exposure
to folic acid did not alter this distribution pattern (Fig. 5F–H).4. Discussion
The data presented in this study provides a novel mechanism
for folic acid-mediated eNOS activation. In the absence of a change
in total eNOS protein, folic acid promotes decreased phosphoryla-
tion of eNOS at negative regulatory sites (Ser116 and Thr497),
increased phosphorylation at positive regulatory sites (Ser635 and
Ser1179) and augmentation of both basal and stimulated eNOS
activity. The data identiﬁes a role for the PI3K/Akt pathway in
maintaining basal eNOS phosphorylation and mediating these folicacid-induced changes. Shifts in speciﬁc posttranslational protein–
protein interactions that favour increased eNOS activity following
folic acid exposure are also described. Importantly, decreased
phosphorylation of Thr497, increased phosphorylation of Ser1179
and increased eNOS activity were observed at a folic acid con-
centration (0.5 μM) easily attainable following clinical supplemen-
tation (Doshi et al., 2002).
Folic acid initially received signiﬁcant attention as a therapeutic
agent in the amelioration of vascular disease due to its role in lowering
plasma homocysteine. Though folic acid doses ranging from 400 mg to
5 mg/day produce similar (25% decrease) homocysteine-lowering
effects (Perrier et al., 2009), supplementary levels of up to 2.5 mg/daily
have largely failed to improve endothelial function in patients with
established cardiovascular disease (Bonaa et al., 2006; Carlsson et al.,
2004; Durga et al., 2005; Dusitanond et al., 2005; Klerk et al., 2005;
Lonn et al., 2006; Toole et al., 2004). Higher folic acid doses of 5 mg/
day or greater are effective in improving cardiovascular outcome
independently of an effect on homocysteine (Bellamy et al., 1999;
Chambers et al., 2000; Doshi et al., 2001, 2002; Moat et al., 2006b).
With regard to underlying mechanisms of action, folate-mediated
peroxynitrite radical scavenging, decreased superoxide generation
(Antoniades et al., 2006) and increased eNOS dimerisation (Moat
et al., 2006b) have been suggested. More recently folic acid-induced
PI3K/Akt-mediated activation of eNOS via phosphorylation at Ser1179
has been suggested (Seto et al., 2010). Data presented in the current
study conﬁrms this observation and demonstrates that folic acid
affects three other eNOS phosphoregulatory sites in a concentration-
dependent manner. While the clinical implications of these ﬁndings
remain to be explored, it is possible that the folic acid-mediated effects
on eNOS activity described herein may underlie the beneﬁcial role of
folic acid in speciﬁc cardiovascular disease conditions such as abdom-
inal aortic aneurysm (Gao et al., 2012).
Human oral supplementation of 5 mg folic acid produces an
acute rise in plasma folate concentration in excess of 0.5 mM (Doshi
et al., 2002), the lowest concentration used in the present study.
While no effect on eNOS phosphorylation at Ser116 was observed
at this concentration, 5 mM and 50 mM folic acid promoted a
signiﬁcant decrease. Although some in vitro studies have shown
that Ser116 dephosphorylation has no effect on eNOS activation
(Boo et al., 2003), others have demonstrated increased endothelial
NO release (Li et al., 2007). The latter corroborates the present
study indicating a role for Ser116 dephosphorylation in folic acid-
mediated increases in eNOS activity. Moreover it is possible that
clinical doses of folic acid below 5 mg/day are not sufﬁcient to
improve endothelial function via this mechanism. However, such
an assumption is based on a 24 h in vitro incubation and may be
due to a lack of acute sensitivity. Continuous daily supplementa-
tion may produce different effects in vivo.
While others have shown protein kinase C (Monti et al., 2010)
and cyclin-dependent kinase 5 (Cho et al., 2010) to be involved in
regulation of eNOS Ser116 phosphorylation, to our knowledge this
is the ﬁrst study to demonstrate increased Ser116 phosphorylation
following PI3K/Akt inhibition. The data clearly demonstrates
an increase in baseline phosphorylation at this epitope in the
presence of both wortmannin and LY294002 and that such
inhibition prevents the folic acid-mediated decrease in phos-
porylation described above. Since basal and stimulated porcine
aortic endothelial cell cGMP production, and the effects of folic
acid thereon, are also inhibited by wortmannin and LY294002, it is
possible that a folic acid/PI3K/Akt/eNOS pSer116 axis exists. As
such this putative pathway provides a novel avenue of investiga-
tion with regard to eNOS control mechanisms.
With regard to eNOS Thr497, signiﬁcant decreases in phos-
phorylation were observed across the folic acid concentration
range. Interestingly, PI3K/Akt inhibition was also accompanied by
similar Thr497 dephosphorylation. While the latter implies that
Fig. 3. Folic acid alters eNOS phosphorylation and kinase activity. Western blotting and densitometric analysis of porcine aortic endothelial cell lysates was used to assess the
effects of PI3K/Akt inhibition with either wortmannin (WM) or LY294,002 (LY) on total eNOS, β-actin and eNOS Ser116p, Thr497p, Ser635p and Ser1179p in the absence
(Control) or presence (+FA) of folic acid (FA, 5 mM, 24 h) (eNOS was normalised β-actin levels and Ser116p, Thr497p, Ser635p and Ser1179p normalised to total eNOS) (A). The
same methodology was used to investigate the effects of folic acid incubation (0–50 μM, 24 h) on total PI3K, Akt and pAktSer473 (B). Appropriate representative blots are
shown. Molecular weight of proteins given in kDa. nPo0.05, nnPo0.01, nnnPo0.001 cf the appropriate “Control”.
Fig. 4. Folic acid alters the interaction of eNOS with regulatory proteins. Western blotting and densitometric analysis of porcine aortic endothelial cell lysates was used to
assess the effects of folic acid (FA, 0–50 μM, 24 h) on total protein levels of eNOS, β-actin and the associated regulatory proteins caveolin-1 (Cav-1), HSP90 and calmodulin
(CaM) (A). Co-immunoprecipitation of eNOS with associated regulatory proteins in these cell lysates, followed by the same analysis, was used to investigate the effects of folic
acid on eNOS/Cav-1, eNOS/HSP90 and eNOS/CaM associations (B). Appropriate representative blots are shown. Molecular weight of proteins given in kDa. nPo0.05,
nnPo0.01, nnnPo0.001 cf the appropriate “Control”.
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Fig. 5. Subcellular location of eNOS and eNOS pSer1179. After incubation of porcine aortic endothelial cells with folic acid (FA, 0 and 5 μM, 24 h) lysates were subject to
discontinuous sucrose gradient ultracentrifugation to separate cholesterol-rich microdomains before western blotting for total eNOS (A), β-actin (B), Ser1179p/eNOS (C) and
caveolin-1 (Cav-1) (D). Densitometric quantiﬁcation was expressed as percentage relative protein across the sucrose gradient. Appropriate representative blots are shown.
Molecular weight of proteins given in kDa. Values represent data from a minimum of two independent experiments. Confocal microscopy was used to conﬁrm the
subcellular location of porcine aortic endothelial cell eNOS (red) in the absence and presence of folic acid (FA, 0.5–50 μM, 24 h) (E–H). The images show that eNOS protein
was found localised to both the perinuclear region (probable Golgi pool) and the cell membrane (probable caveolar pool). (For interpretation of the references to color in this
ﬁgure legend, the reader is referred to the web version of this article.)
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phorylation, it also suggests that the effect of folic acid at this
residue is PI3K/Akt independent. This indicates an important
divergence with regard to folic acid and its role in moderating
eNOS activity. Further in depth studies will be required to address
the mechanisms and biochemical mediators involved.Phosphorylation of eNOS at Ser635 is described as one of the
most important points of regulation of basal NO production and in
this respect is independent of phosphorylation at other sites
(Bauer et al., 2003) and/or intracellular calcium release (Boo
et al., 2003). Data presented here shows folic acid to promote
increased Ser635 phosphorylation while PI3K/Akt inhibition does
S.Y. Taylor et al. / European Journal of Pharmacology 714 (2013) 193–201200the opposite, and indeed prevents the folic acid-mediated changes
at this residue. This suggests the presence of a folic acid/PI3K/Akt/
eNOS pSer635 axis. However, that only the highest folic acid
concentrations produce minor increases in phosphorylation,
whereas dephosphorylation occurs across the concentration range,
questions the relevance of such a pathway. Interestingly previous
studies have indicated that PI3K/Akt does not directly phosphor-
ylate Ser635 (Michell et al., 2002), rather PI3K/Akt-dependent
mechanisms may involve interactions with other signalling
pathways or cooperative phosphorylation mechanisms (Zhang
and Hintze, 2006). While the latter requires further study, that
Ser635 phosphorylation is involved in basal eNOS regulation
indicates that changes at this residue may play an important role
in optimising normal endothelial function. Though a lack of effect
of 0.5 mM folic acid may again question in vivo relevance, the same
argument as to continuous daily supplementation described above
would apply.
Phosphorylation at Ser1179 is suggested to play the most
signiﬁcant role in modifying eNOS activity (Lane and Gross,
2002; McCabe et al., 2000). The data presented here conﬁrms
that folic acid positively regulates Ser1179 phosphorylation and
increased eNOS activity at all concentrations used (0.5–50 μM).
Indeed it is evident that Ser1179 is the most “folic acid-sensitive”
residue amongst those investigated with maximum phosphoryla-
tion levels following folic acid exposure around 3–4 fold greater
than controls.
A signiﬁcant role for Akt in mediating eNOS phosphorylation at
Ser1179 has been widely described. It is therefore not surprising
that PI3K/Akt inhibition in the experiments described here is
accompanied by a decrease in phosphorylation at this epitope.
Moreover, that this inhibition prevents any folic acid-induced
increase in Ser1179 phosphorylation suggests the existence of a
further folic acid/PI3K/Akt/eNOS pSer1179 axis. Given the “folic
acid-sensitivity” of eNOS Ser1179, such an axis would have far
reaching effects on eNOS activity.
The data presented here also demonstrates signiﬁcant
increases in both basal and calcium ionophore-induced cGMP
production following exposure to folic acid in the absence of
increased soluble guanylate cyclase expression. Furthermore, that
L-NAME inhibits folic acid-mediated increases in both basal and
ionophore-induced cGMP production would indeed imply that
these measurements reﬂect changes in eNOS activity. Importantly,
our previous studies would seem to rule out a role for folic acid-
mediated stabilisation/regeneration of the eNOS co-factor tetra-
hydrobiopterin in this process (Moat et al., 2006a). Moreover,
while it cannot be completely ruled out, a direct antioxidant role
for folic acid is also highly unlikely (Moat et al. 2006a). That
notwithstanding, given the negative effect of PI3K/Akt inhibition
on porcine aortic endothelial cell cGMP production presented
here, the folic acid/PI3K/Akt/eNOS phosphorylation axes described
above provide important and novel pathways that may underlie
the positive effects of folic acid in improving endothelial function.
Data from the pharmacological inhibitory experiments
described here provide signiﬁcant evidence of a deﬁnitive role
for PI3K/Akt in mediating the effects of folic acid. However, with
regard PI3K/Akt activity, signiﬁcant increases in the Ser473-
phosphorylated epitope of Akt were evident only in the presence
of the highest concentration of folic acid. This anomaly is most
likely caused by the sensitivity of our assay system (the western
blots do indicate the presence of Ser473pAkt at lower folic acid
concentrations) and should not detract from the importance of the
other observations presented.
Undoubtedly the aforementioned changes in eNOS phos-
phorylation have a signiﬁcant effect on enzyme activity. However,
as mentioned above, there are other mechanisms of eNOS regula-
tion, in particular the interaction with other proteins (Fulton et al.,2001; Kone et al., 2003) and the effects of subcellular localization
(Shaul, 2002). It is clear from the present studies that folic acid
promotes a signiﬁcant increase/decrease in the interaction of eNOS
with HSP90/caveolin-1 respectively, while that with calmodulin is
unaffected. However, the lack of effect of 50 mM folic acid on the
eNOS/HSP90 interaction is puzzling. It is possible that this very
high concentration promotes more rapid eNOS/HSP90 interactions
and that these are missed by our 24 h “snap-shot”. Without
signiﬁcant further experiments, out of the scope of the present
study, it is impossible to conﬁrm this. However, given the other
signiﬁcant effects mediated by 50 mM folic acid, an HSP90 inde-
pendent mechanism at this concentration seems unlikely.
Importantly the changes in protein–protein interactions described
here are not a consequence of alterations in transcription/transla-
tion and occur in the absence of an obvious change in the
subcellular distribution of eNOS protein. Given that several other
stimuli are well reported to have similar effects on the HSP90/
eNOS and caveolin-1/eNOS interactions, thus increasing NO synth-
esis (Brouet et al., 2001; Forstermann et al., 1991; Garcia-Cardena
et al., 1998; Michel et al., 1997b; Takahashi and Mendelsohn, 2003)
suggests that this action of folic acid could also play a signiﬁcant
role in improving endothelial function in the studies described
above.5. Conclusion
The present study demonstrates that folic acid modulates eNOS
activity via both positive and negative phosphorylation events that
involve important intracellular protein kinase-dependent signal-
ling axes. Furthermore, folic acid also inﬂuences changes in
important eNOS protein interactions which would ultimately lead
to increased enzyme activity. Notably these data would implicate
folic acid in the optimisation of normal endothelial function
and the possible prevention of an initial, and deleterious,
cardiovascular event.Sources of funding
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